Zymeworks, Roche, ZW209, DLL3, Trispecific T-Cell Engager, TriTCE, T-Cell Engager, Small Cell Lung Cancer, Neuroendocrine Tumors, Cancer Immunotherapy, Multispecific Antibodies,

VANCOUVER, British Columbia — October 23, 2026 Zymeworks Inc., a biotechnology company developing multifunctional biotherapeutics and managing a portfolio...